<DOC>
	<DOCNO>NCT02224105</DOCNO>
	<brief_summary>The general aim current study investigate safety tolerability , pharmacodynamics ( endotoxin-induced inflammatory response single intravenous bolus administration 2 ng/kg body weight Escherichia coli lipopolysaccharide ( LPS ) ) BI 653048 BS H3PO4 capsule healthy male subject follow oral administration multiple rise dos 25 mg 200 mg three day compare active comparator prednisolone placebo . Pharmacodynamics assess investigate influence LPS administration inflammatory parameter . More specifically , evaluate whether extent symptom induce LPS challenge attenuate ascend BI 653048 BS H3PO4 dose use prednisolone positive control placebo negative control . A secondary objective exploration pharmacokinetics BI 653048 BS , investigation pharmacodynamic parameter ( biomarker ) tolerability LPS .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamics Pharmacokinetics BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate body temperature ) , 12lead ECG , clinical laboratory test 2 . Age ≥18 Age ≤50 year 3 . Body mass index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Any finding medical examination ( include blood pressure , pulse rate , orthostatic test , body temperature ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackouts 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 11 . Participation another trial investigational drug within 30 day prior administration trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Inability refrain smoke 1 day prior first drug administration discharge study site 14 . Alcohol abuse ( 60 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance 19 . Inability comply dietary regimen trial site</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>